Laserscope's Greenlight PV(R) Laser System Shows Potential for Treating Kidney Tumors
September 20 2005 - 8:00AM
PR Newswire (US)
Researchers at the Cleveland Clinic Report Positive Results of
Feasibility Trial SAN JOSE, Calif., Sept. 20 /PRNewswire-FirstCall/
-- Laserscope (NASDAQ:LSCP), a pioneer in the development and
commercialization of minimally-invasive medical devices, including
medical lasers and advanced fiber-optic delivery devices, today
announced that recent animal trials conducted by researchers at the
Cleveland Clinic Foundation ("Cleveland Clinic") demonstrated the
successful application of the Company's GreenLight PV(R) laser
system for laparoscopic partial nephrectomy in treating kidney
masses or tumors. The findings were reported in the September 2005
issue of The Journal of Urology. Based on the trial study,
Cleveland Clinic researchers concluded that the hemostatic, or
blood clotting, properties specific to the GreenLight(TM) laser
show a "real potential for clinical application."(1) The study
demonstrated that Laserscope's GreenLight PV(R) laser is feasible,
in most cases, for the resection and vaporization of kidney tissue
without having to interrupt blood supply to the kidney, thereby
limiting the risk of organ damage. Blood loss during the laser
treatment was found to be minimal and all study animals survived
the one-month follow-up without complications. Dr. Alireza
Moinzadeh, earlier a fellow at the Cleveland Clinic, and now Head
of the Section of Laparoscopic and Robotic Surgery at SUNY,
Syracuse, and lead investigator in the study commented that, "This
demonstration of the efficacy of KTP laser during laparoscopic
partial nephrectomy without renal hilar clamping represents a
significant step forward in the field." Dr. Inderbir S. Gill, head,
section of laparoscopic and robotic surgery at the Cleveland Clinic
and senior author of the study added that, "The potential
advantages of this new technique include optimization of renal
function preservation, the complete eradication of cancer while
eliminating the need for skill intensive suturing, thereby allowing
a broader group of urologic surgeons to adopt laparoscopic partial
nephrectomy." "We are excited about this potential new application
for our GreenLight PV(R) laser system, as well as the publication
of the study's results in the Urology industry's pre-eminent
academic journal," said Eric Reuter, President and Chief Executive
Officer of Laserscope. "We have believed for some time that the
scientific properties of our GreenLight(TM) laser make it
appropriate for treating a number of disorders, and have devoted
appropriate research and development efforts toward identifying
them. Although additional research is needed before we can
commercialize the GreenLight PV(R) laser for the treatment of
kidney tumors, we believe that this study is the first step toward
educating the marketplace about its potential benefits. With more
than 35,000 new cases of kidney tumors being diagnosed each year in
the United States, we believe this is an important finding." About
Laserscope Laserscope designs, manufactures, sells and services on
a worldwide basis an advanced line of minimally-invasive medical
products, including medical laser systems and related energy
delivery devices for the office, outpatient surgical center, and
hospital markets. More information about Laserscope can be found on
the Company's web site at http://www.laserscope.com/. Safe Harbor
Statement This press release contains forward-looking information
within the meaning of Section 21E of the Securities Exchange Act of
1934 and is subject to the safe harbor created by this section.
These forward-looking statements include statements about
Laserscope's future business, competition, expected continued
momentum of Laserscope's business and growth and market
penetration. These statements are subject to a number of risks and
uncertainties, including among other risks: uncertainties regarding
the viability of new applications for Laserscope's technology, the
introduction of new technologies competitive to Laserscope's
products and the degree to which the Company's current and new
products are accepted by customers, which could affect the level of
demand for our products; our dependence on sole source providers
for key components and products; risk of reductions in government
and private insurance reimbursement of hospitals and physicians for
health care costs, which may negatively impact hospitals and
physicians decisions to purchase our products reducing adoption
rates and sales growth; risks that we may be unable to protect
adequately the integrity, safety and proper use of our disposable
fiber optic delivery device with the GreenLight PV(R) laser system,
which could result in negative patient outcomes and reduce our
disposable fiber recurring revenue stream; risks that patents and
licenses that we hold may be challenged, invalidated or
circumvented or that we may become the subject of intellectual
property litigation; and uncertainties that new products will
receive regulatory approval in applicable jurisdictions. Actual
results may differ materially due to these and other factors. The
matters discussed in this press release also involve risks and
uncertainties described from time to time in Laserscope's filings
with the Securities and Exchange Commission. In particular, see the
Risk Factors described in Laserscope's most recent Quarterly Report
on Form 10-Q and Annual Report on Form 10-K. Copies of Laserscope's
public disclosure filings with the SEC, including the most recent
Annual Report on Form 10-K and the most recent forms 10-Q are
available upon request from its Investor Relations Department at
its website at http://www.laserscope.com/ or at the SEC's website
at http://www.sec.gov/. Laserscope assumes no obligation to update
the forward-looking information contained in this press release.
(1) Moinzadeh A. et al, Potassium-Titanyl-Phosphate Laser
Laparoscopic Partial Nephrectomy without Hilar Clamping in the
Survival Calf Model -- The Journal of Urology -- Vol. 174,
1110-1114 At Laserscope: At Financial Relations Board: Eric Reuter,
President & CEO Tricia Ross, Analyst Contact Derek Bertocci,
CFO (617) 520-7064 (408) 943-0636 Laurie Berman, General
Information (310) 854-8315 DATASOURCE: Laserscope CONTACT: Eric
Reuter, President & CEO, or Derek Bertocci, CFO, both of
Laserscope, +1-408-943-0636; or analysts, Tricia Ross,
+1-617-520-7064, or general information, Laurie Berman,
+1-310-854-8315, both of Financial Relations Board, for Laserscope
Web site: http://www.laserscope.com/
Copyright
Laserscope (NASDAQ:LSCP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Laserscope (NASDAQ:LSCP)
Historical Stock Chart
From Jul 2023 to Jul 2024